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Insulin protects acinar cells during pancreatitis by
preserving glycolytic ATP supply to calcium pumps
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Acute pancreatitis (AP) is serious inflammatory disease of the pancreas. Accumulating
evidence links diabetes with severity of AP, suggesting that endogenous insulin may be
protective. We investigated this putative protective effect of insulin during cellular and in vivo
models of AP in diabetic mice (Ins2Akita) and Pancreatic Acinar cell-specific Conditional
Insulin Receptor Knock Out mice (PACIRKO). Caerulein and palmitoleic acid (POA)/ethanol-
induced pancreatitis was more severe in both Ins2Akita and PACIRKO vs control mice, sug-
gesting that endogenous insulin directly protects acinar cells in vivo. In isolated pancreatic
acinar cells, insulin induced Akt-mediated phosphorylation of 6-phosphofructo-2-kinase/
fructose-2,6-biphosphatase 2 (PFKFB2) which upregulated glycolysis thereby preventing
POA-induced ATP depletion, inhibition of the ATP-dependent plasma membrane Ca2+
ATPase (PMCA) and cytotoxic Ca2+ overload. These data provide the first mechanistic link
between diabetes and severity of AP and suggest that phosphorylation of PFKFB2 may
represent a potential therapeutic strategy for treatment of AP.
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Pancreatitis is an inflammatory disease of the exocrinepancreas which in most cases is initiated by bile acid refluxfrom gall stones or fatty acid/ethanol metabolites from
excessive alcohol and fat consumption1. Severe acute pancreatitis
(SAP) is characterised by pancreatic necrosis and multiple organ
failure, which increases mortality and prolongs critical care
occupancy. In the USA SAP accounts for 1.4 million hospital days
at a cost of $2.6 billion every year2. There is no imminent cure
and treatment is restricted to nutritional support and fluid
resuscitation3,4. Clearly a radical approach to the treatment of SAP
is urgently required to improve survival and reduce critical care
occupancy. Impaired metabolism and cytotoxic Ca2+ ([Ca2+]i)
overload in pancreatic acinar cells are central events regardless of
the causative factor1. Metabolism and [Ca2+]i are linked by the
ATP-driven plasma membrane Ca2+ ATPase (PMCA), which
prevents cytotoxic Ca2+ overload. Therefore, restoration of acinar
cell metabolism and protection of PMCA represents an attractive
therapeutic strategy, which might be achieved by insulin.
Using cellular models of pancreatitis our previous studies
revealed that insulin protects acinar cells from cellular injury5,6.
However, it is unclear from these studies in isolated pancreatic
acinar cells whether endogenous insulin release has any protective
effect in vivo and the specific molecular mechanism remains
unknown. Although pancreatitis can lead to type 3c diabetes, due
to collateral pancreatic β-cell injury and the loss of insulin
secretion7,8, emerging evidence from clinical9–14 and animal
studies15–17 suggest that diabetes increases the severity of AP and
thus endogenous insulin may be protective.
However, it is very difficult to separate the systemic effects of
hyperglycaemia, reduced insulin secretion (type-1 diabetes) or
reduced insulin sensitivity (type-2 diabetes), from any putative
direct protective effects of insulin on pancreatic acinar cells. This
was achieved in the current study by inducing experimental AP in
Pancreatic Acinar cell-specific Conditional Insulin Receptor
Knock Out mice (PACIRKO) in which insulin receptors (IRs)
were deleted specifically in acinar cells using a tamoxifen-induced
Cre-lox-based gene deletion system18. Results show that pan-
creatitis was more severe in both Ins2Akita mice (type-1 diabetic
mouse model) and in PACIRKO mice. This was due to a loss of
insulin-induced, Akt-mediated phosphorylation of the key gly-
colytic enzyme, 6-phosphofructo-2-kinase/fructose-2,6-bispho-
sphatase 2 (PFKFB2) in pancreatic acinar cells. This is sufficient
to drive glycolytic flux and maintain the glycolytic ATP supply to
the plasma membrane Ca2+ pumps (PMCA), thereby preventing
cytotoxic Ca2+ overload and necrotic cell death even in the face
of impaired mitochondrial function. Collectively, this provides a
strong mechanistic link between diabetes and the severity of acute
pancreatitis and suggests that the phosphorylation of PFKFB2, by
insulin or insulin-mimetics, and the preservation of acinar cell
ATP, may represent a potential therapeutic strategy for the
treatment of AP.
Results
Pancreatitis is worse in diabetic Ins2Akita mice. To test whether
endogenous insulin had any protective effect during AP, we first
induced experimental pancreatitis in parallel groups of age-
matched type-1 diabetic Ins2Akita mice vs control C57BL/6
wildtype mice (WT). This was done using the classical caerulein-
induced hyperstimulation model of AP. Ins2Akita mice were all
confirmed to be hyperglycaemic, regardless of whether pancrea-
titis was induced (423 ± 47 mg/dl, caerulein treatment, n= 4; and
443 ± 82 mg/dl, PBS treatment, n= 3) compared to WT mice
(125 ± 17 mg/dl, caerulein treatment, n= 6; and 145 ± 31mg/dl,
PBS treatment, n= 5; Fig. 1a).
For all parameters measured, pancreatitis was potentiated in
Ins2Akita mice compared to corresponding WT control mice
(Fig. 1). Specifically, caerulein induced a 69 ± 6 % increase in
oedema (pancreas wet/dry weight ratio) in Ins2Akita mice
compared to 24 ± 4% increase in WT control mice (Fig. 1b).
Interestingly, in Ins2Akita mice without pancreatitis (injected with
phosphate-buffered saline (PBS)), pancreas wet/dry weight ratio
was lower (2.59 ± 0.19) compared to WT mice (3.13 ± 0.09;
Fig. 1b), suggesting the pancreas of Ins2Akita mice is more
dehydrated than WT pancreas. In addition, qPCR of pancreatic
tissue mRNA revealed that pancreatic tissue cytokine expression,
including TNFα (Fig. 1c) and IL-6 mRNA expression was
markedly potentiated in Ins2Akita mice compared to WT mice
(Fig. 1d). Histologically, numerous features of pancreatitis also
appeared to be aggravated in Ins2Akita mice compared to WT
mice. Haematoxylin and Eosin (H&E) staining of formalin-fixed
paraffin-embedded (FFPE) pancreas tissue revealed that in WT
mice caerulein induced intralobular oedema with ‘patchy’ areas of
severe tissue injury interspersed by normal tissue (Fig. 1f
compared to e). However, in Ins2Akita mice, caerulein induced
more severe tissue oedema that was more widespread across the
tissue, rather than being “patchy” as was the case with the WT
pancreas (Fig. 1j compared to i). There were clear signs of vacuole
formation (red arrow, Fig. 1j) and inflammatory cell infiltration
(yellow arrow, Fig. 1j), which was confirmed using CD45
immunohistochemistry of pancreas tissue counterstained with
haematoxylin (Fig. 1g–l). CD45 is a non-specific cell surface
marker expressed on haematopoietically-derived inflammatory
cells including, neutrophils, macrophages, eosinophils19. Consis-
tent with these observations, pancreatitis was further quantified
histologically using a well-validated histology injury score of H&E
stained slides20–22. These data revealed that cerulein induced a
consistently higher injury score in diabetic Ins2Akita mice
compared to WT mice for all four criteria (Fig. 1m–p).
Functional characterization of PACIRKO mice. We next wan-
ted to separate the confounding effects of hyperglycaemia, or
reduced systemic insulin, from a loss of any direct protection of
insulin on acinar cells. This was achieved using PACIRKO mice,
in which the insulin receptor (IR) was specifically deleted in
pancreatic acinar cells of adult mice using a tamoxifen-inducible
gene deletion (Supplementary Information). Insulin receptor (IR)
expression was greatly reduced following tamoxifen administra-
tion (daily oral gavage or tamoxifen feed for 4 consecutive days)
in pancreatic tissue (Fig. 2a, b) and acinar cells from PACIRKO
mice compared to corresponding littermate control IRlox/lox mice
or the feeder Ela-CreER+/ mouse line (Fig. 2c; assessed by western
blotting). Moreover, IR expression is specifically reduced in the
pancreas, as expression in the spleen, liver and kidney remains
normal (Fig. 2c). This reduced IR expression occurred regardless
of whether pancreatitis was induced with caerulein (Fig. 2a).
Importantly, unlike Ins2Akita mice, plasma glucose was normal in
PACIRKO mice (Fig. 2d).
Pancreatitis is worse in non-diabetic PACIRKO mice lacking
acinar IRs. Similar to Ins2Akita diabetic mice, pancreatitis was
worse in PACIRKO mice, either induced by caerulein (Fig. 3) or
by fatty acid/ethanol20 (Fig. 4), compared to corresponding age-
matched littermate control mice (IRlox/lox). Specifically, the
caerulein-induced increase in pancreas wet/dry weight ratio was
markedly potentiated in PACIRKO mice (51 ± 2 %) compared to
IRlox/lox mice (18 ± 3 %, Fig. 3a). PACIRKO pancreas wet/dry
weight ratio (2.61 ± 0.08) without pancreatitis (PBS-induced) was
lower compared to IRlox/lox mice (2.96 ± 0.09). This suggests that
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PACIRKO mouse pancreas was more dehydrated than IRlox/lox,
similar to diabetic Ins2Akita mice.
In addition, pancreatic tissue cytokine expression, including
TNFα (Fig. 3b), IL-6 (Fig. 2c) and IL-1β mRNA expression
(Fig. 3d) was markedly potentiated in PACIRKO mice compared
to IRlox/lox mice. However, 18S ribosomal RNA (18S rRNA;
Fig. 3e) remained unchanged suggesting that cellular RNA
remains relatively intact during pancreatitis. Histologically,
numerous features of pancreatitis also appeared to be worse in
PACIRKO mice (Fig. 3k), compared to IRlox/lox (Fig. 3g),
similarly to diabetic Ins2Akita mice. H&E staining revealed
extensive tissue oedema and severe injury (vacuoles, necrosis,
inflammatory cell infiltration and haemorrhagic areas; Fig. 3k)
compared to the focal areas of less severe oedema/injury in IRlox/
lox mice (Fig. 3g). Inflammatory cell infiltration was further
confirmed in PACIRKO mice by CD45 immunohistochemistry
vs IRlox/lox mice (Fig. 3h–m) and finally, histology injury
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Fig. 1 Caerulein-induced pancreatitis is more severe in type-1 diabetic Ins2Akita mice vs wild type (WT) control mice. Pancreatitis was induced in WT
and type-1 diabetic Ins2Akita mice by caerulein (Caer; 50 µg/Kg × 8 hourly IP injections over 2 days) or phosphate-buffered saline (PBS) as a control and
blood/tissue was harvested 24 h after the last injection. Blood glucose (a) and multiple readouts of pancreatitis were assessed (b–p). These include;
pancreatic tissue oedema (wet/dry weight ratio, b), cytokine expression (qPCR of tissue mRNA; TNFα, c; IL-6, d), histological signs of injury (haematoxylin
and eosin (H&E), e, f, i and j), immunohistochemistry of the inflammatory marker, CD45 (brown) (g, h, k and l). Yellow and red arrows in j and l indicate
vacuole formation and inflammatory cell infiltration, respectively. m–p Histology injury scores (where 3 is the most severe) for oedema (m), inflammatory
cell infiltration (n), necrosis (o), and total score (p; sum of other scores). Group sizes were: WT PBS, n= 5; WT Caer, n= 6; Ins2Akita PBS, n= 3; Ins2Akita
Caer, n= 4. Significance (exact p values as indicated) was determined by one-way ANOVA with Sidak’s multiple comparisons. Data are presented as mean
value ± SEM.
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pancreatitis was more severe in PACIRKO mice vs IRlox/lox mice
(Fig. 3n–q).
We next tested the effect of the more aetiologically relevant
palmitoleic acid/ethanol (POA/ETOH) model20. This model was
further optimised using lower doses of both POA and ETOH,
which produced a more specific pancreatitis, and less peripheral
organ injury independent of pancreatitis (Fig. S1 and Supple-
mentary Information). Similar results were obtained using the
POA/ETOH-induced model of pancreatitis to those obtained
with caerulein. In PACIRKO mice, there was a potentiation of
POA/ETOH-induced pancreas wet/dry weight ratio (58 ± 4% vs
22 ± 2% in IRlox/lox mice; Fig. 4a), pancreatic tissue cytokine
expression (Fig. 4b–e), histological features of pancreatitis (H&E;
Fig. 4f–k) and CD45-positive staining (Fig. 4h–m). Likewise,
there was a similar overall trend in the POA/ETOH-induced
histology injury scores in PACIRKO vs IRlox/lox mice (Fig. 4n–q).
Insulin-induced protection against POA-induced cytotoxic Ca2
+ overload is abolished in acinar cells from PACIRKO mice.
Since pancreatitis was more severe in PACIRKO mice lacking
acinar cell IRs, we next wanted to investigate the mechanism for
the protective effect of insulin on acinar cells from IRlox/lox mice
vs PACIRKO mice. This was achieved using ‘cellular models’ of
pancreatitis in which isolated acinar cells (from IRlox/lox vs
PACIRKO mice), were pre-treated with or without insulin (10
nM for 15 min) followed by POA to induce cytotoxic Ca2+
overload as a readout of cellular injury (Fig. 5). On average, 30
µM POA induced a robust increase in [Ca2+]i by 600 ± 73 nM
(Fig. 5a–e), which was dramatically reduced to 103 ± 50 nM
(Fig. 5b–e), in the presence of insulin (Fig. 5f; area under the
curve (AUC); 397 ± 53 µM.s with POA alone vs 100 ± 29 µM.s
with insulin (p < 0.05)). However, this insulin-mediated protec-
tion was completely abolished in acinar cells from PACIRKO
mice (Fig. 5d; POA alone increased [Ca2+]i to 520 ± 56 nM
(AUC; 315 ± 26 µM.s), while POA in the insulin-treated group
increased [Ca2+]i to 625 ± 44 nM (AUC; 361 ± 36 µM.s; Fig. 5).
Collectively, these data clearly show that insulin protects mouse
pancreatic acinar cells against POA-induced cytotoxic [Ca2+]i
overload, which is abolished in acinar cells from PACIRKO mice
lacking acinar IRs.
Insulin-induced protection against POA-induced PMCA inhi-
bition is abolished in acinar cells from PACIRKO mice. To test
whether the insulin protection of POA-induced Ca2+ overload in
acinar cells was due to protection of PMCA activity we utilised a
similar in situ [Ca2+]i clearance assay to our previous
studies5,6,23. Under these conditions, 30 µM POA caused a dra-
matic inhibition of relative [Ca2+]i clearance, and thus PMCA
activity, in cells from both IRlox/lox mice (13 ± 6%; Fig. 6b,
compared to time-matched control, 101 ± 2%, Fig. 6a) and
PACIRKO mice (10 ± 3%; Fig. 6e compared to time-matched
control, 98 ± 1%, Fig. 6d). However, this POA-induced inhibition
of PMCA activity was completely abolished following pretreat-
ment with 10 nM insulin in cells from IRlox/lox mice (100 ± 6%;
Fig. 6c) but not PACIRKO mice (21 ± 5%; Fig. 6f). These data
suggest that insulin protects the PMCA from inhibition by POA
which is specifically mediated through IRs, as this protection is
abolished in PACIRKO mice lacking IRs.
Insulin-induced protection against POA-induced ATP deple-
tion is abolished in acinar cells from PACIRKO mice. We next
wanted to test whether insulin prevents POA-induced ATP
depletion in IRlox/lox mouse pancreatic acinar cells, using the
firefly luciferase-based chemiluminescence assay5,6,23. In acinar
cells from IRlox/lox mice, POA caused a concentration-dependent
ATP depletion between 1–100 µM which generated an average
IC50 of 12.2 ± 3.3 µM and Hill slope of −1.58 ± 0.3 (Fig. 7a–c).
Pre-treatment of cells with 10 nM insulin caused a rightward shift
in the concentration-response curve and significantly increased
the average IC50 to 49.4 ± 7.4 µM (p < 0.05; Hill slope of −2.99 ±
0.84; Fig. 7a–c). However, in acinar cells from PACIRKO mice,
POA caused a similar concentration-dependent ATP depletion
(IC50 of 20.6 ± 4.5 µM and Hill slope of −0.94 ± 0.08; Fig. 7b, c,
black circles), which was unaffected by insulin pre-treatment
(IC50 of 14.6 ± 3.4 µM and Hill slope of −0.87 ± 0.04; Fig. 7b, c).
This suggests that insulin preserves ATP over the same POA
concentration range (3–100 μM) that induces cytotoxic Ca2+
overload and inhibition of PMCA.
Effect of insulin on cellular bioenergetics in pancreatic acinar
cells. To further explore the effect of insulin on acinar cell
metabolism we first measured NAD(P)H autofluorescence as an
indirect measure of glycolytic vs mitochondrial metabolism5. The
major source of cellular NAD(P)H is from the mitochondrial
Krebs cycle whereas a minor source comes from the glycolytic
enzyme, glyceraldehyde phosphate dehydrogenase (GAPDH).
Therefore, treatment of cells with the protonophore and mito-
chondrial uncoupler, CCCP (4 µM), causes rapid consumption of
mitochondrial NAD(P)H, and thus a reduction in NAD(P)H
autofluorescence. CCCP acts by dissipating the mitochondrial
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Fig. 2 PACIRKO mice that lack pancreatic acinar cell insulin receptors are
normoglycaemic. a Insulin receptor (IR) expression (western blot using
anti-IRβ antibody) in pancreas tissue from double floxed insulin receptor
(IRlox/lox) mice vs Pancreatic Acinar Conditional Insulin Receptor Knock
Out (PACIRKO) mice following administration of tamoxifen for 4 days (oral
gavage or tamoxifen feed) with (+) or without (−) caerulein (Caer; 50 µg/
Kg × 8 hourly IP injections over 2 days) to induce acute pancreatitis, or PBS.
Western blotting with anti-cyclophilin-A was used as a loading control. IR
expression was semi-quantified by normalizing band intensities to the
corresponding cyclophilin-A band and further normalisation to the mean of
IRlox/lox (b). c IR expression was also compared between lysates from
pancreatic acinar cells and tissue from Ela-CreER/+ mice, IRlox/lox and
PACIRKO and also liver, spleen and kidney tissue. Actin was used as a
loading control (lower panel, c). For each western blot of IR in a, c, the
corresponding loading control (cyclophilin-A in a and actin in b) were from
the same gel (membrane cut and incubated with corresponding antibody)
and are representative of three separate experiments. d Blood glucose in
IRlox/lox vs PACIRKO mice, with caerulein (grey bars) or PBS white bars).
Group sizes were: IRlox/lox PBS, n= 15; IRlox/lox Caer, n= 12; PACIRKO PBS,
n= 13; PACIRKO Caer, n= 12. Data are presented as mean value ± SEM.
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-021-24506-w
4 NATURE COMMUNICATIONS |         (2021) 12:4386 | https://doi.org/10.1038/s41467-021-24506-w |www.nature.com/naturecommunications
The uncoupling of ATP synthesis from the electron transport
chain/oxygen consumption results in mitochondrial respiration
operating at ‘full tilt’ in an attempt to maintain the mitochondrial
proton gradient. The resulting increased mitochondrial NADH
consumption by the electron transport chain ultimately leads to
mitochondrial NADH depletion. CCCP-induced NADH deple-
tion could therefore be described as a surrogate for mitochondrial
bioenergetics and thus ATP production (Fig. 7d). Subsequent
inhibition of GAPDH with iodoacetate (IAA, 2 mM), caused a
further smaller decrease in NAD(P)H autofluorescence (Fig. 7d).
As GAPDH is a major source of glycolytic NADH, IAA-induced
NADH depletion could be described as a surrogate for glycolytic
bioenergetics and thus ATP production. The relative CCCP vs
IAA-induced changes in NAD(P)H autofluorescence were
quantified and normalised to the total decrease in NAD(P)H
autofluorescence (Fig. 7f–i) and thus represents the relative
mitochondrial vs glycolytic metabolism. In untreated control cells
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Fig. 3 Caerulein-induced pancreatitis is more severe in PACIRKO vs IRlox/lox mice. Pancreatitis was induced in control double floxed insulin receptor
(IRlox/lox) mice vs Pancreatic Acinar Conditional Insulin Receptor Knock Out (PACIRKO) mice that lack insulin receptors (IRs) by caerulein (Caer; 50 µg/
Kg × 8 hourly IP injections over 2 days) or phosphate-buffered saline (PBS) as a control and blood/tissue was harvested 2 and 24 h after the last injection.
Multiple readouts of pancreatitis include; pancreatic tissue oedema (wet/dry weight ratio, a), cytokine expression (qPCR of tissue mRNA; TNFα, b; IL-6, c,
IL-1β, d; and the housekeeping 18 S rRNA, e), histological signs of injury (haematoxylin and eosin (H&E), f, g, j and k), immunohistochemistry of the
inflammatory marker, CD45 (brown) (h, i, l and m). n–q Histology injury scores (where 3 is the most severe) for oedema (n), inflammatory cell infiltration
(o), necrosis (p), and total score (q; sum of other scores). Group sizes were: 2 h harvest, IRlox/lox PBS, n= 6; IRlox/lox Caer, n= 6; PACIRKO PBS, n= 5;
PACIRKO Caer, n= 6; 24 h harvest, IRlox/lox PBS, n= 5; IRlox/lox Caer, n= 5; PACIRKO PBS, n= 6; PACIRKO Caer, n= 6. Significance (exact p values as
indicated) was determined by one-way ANOVA with Sidak’s multiple comparisons. Data are presented as mean value ± SEM.
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and IAA a 12.1 ± 1.1% decrease in NAD(P)H autofluorescence,
respectively (Fig. 7d–f), consistent with predominantly mito-
chondrial metabolism and presumably ATP production. In cells
pre-treated with 10 nM insulin for 15 min, the CCCP-induced
decrease in NAD(P)H autofluorescence was markedly reduced to
only 62.1 ± 2.3%, whereas the IAA-induced decrease in NAD(P)H
autofluorescence increased to 38 ± 2.3% (Fig. 7e, f), suggesting
that insulin mediates a metabolic switch towards glycolysis.
However, this insulin-mediated switch towards glycolysis was
abolished in acinar cells from PACIRKO mice (Fig. 7g–i).
Although these NADH autofluorescence responses are a
convenient surrogate of mitochondrial vs glycolytic bioenergetics,
we next wanted to investigate whether this translated to changes
in cellular ATP. We used the same experimental strategy of
treating cells with CCCP followed by IAA, but instead in
magnesium green (MgGreen)-loaded acinar cells, which is used as
an indirect measure of cellular ATP. This is because most cellular
ATP exists as MgATP, therefore ATP depletion causes an
increase in free Mg2+ concentration and thus MgGreen
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Fig. 4 POA/ethanol-induced pancreatitis was more severe in PACIRKO vs IRlox/lox mice. Pancreatitis was induced in IRlox/lox and PACIRKO mice by 2
hourly IP injections of 100 µg/Kg POA in ethanol (0.8 g/Kg) or corresponding PBS control and blood/tissue was harvested 2 and 24 h after the last
injection. Multiple readouts of pancreatitis include; pancreatic tissue oedema (wet/dry weight ratio, a), cytokine expression (qPCR of tissue mRNA; TNFα,
b; IL-6, c, IL-1β, d; and the housekeeping 18S rRNA, e), histological signs of injury (haematoxylin and eosin (H&E), f, g, j and k), immunohistochemistry of
the inflammatory marker, CD45 (brown) (h, i, l and m). n–q Histology injury scores (where 3 is the most severe) for oedema (n), inflammatory cell
infiltration (o), necrosis (p), and total score (q; sum of other scores). Group sizes were: 2 h harvest, IRlox/lox PBS, n= 6; IRlox/lox POA, n= 7; PACIRKO PBS,
n= 4; PACIRKO Caer, n= 6; 24 h harvest, IRlox/lox PBS, n= 6; IRlox/lox Caer, n= 6; PACIRKO PBS, n= 6; PACIRKO Caer, n= 6 Significance (exact p values
as indicated) was determined by one-way ANOVA with Sidak’s multiple comparisons. Data are presented as mean value ± SEM.
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CCCP-induced and IAA-induced increases in MgGreen fluores-
cence were normalised to the total change in MgGreen
fluorescence (Fig. S6c). In agreement with the changes in NADH
autofluorescence, insulin treatment (10 nM for 15 min) reduced
the CCCP-induced increase in MgGreen fluorescence (70 ± 3.7%
to 32 ± 1.6%; Fig. S6), a measure of mitochondrial ATP depletion,
but enhanced the IAA-induced increase in MgGreen fluorescence
(30 ± 3.7% to 68 ± 1.5%; Fig. S6), a measure of glycolytoc ATP
depetion. These data show that insulin treatment switches
pancreatic acinar cell metabolism towards glycolysis, which is
sufficient to preserve cellular ATP to fuel the PMCA and
maintain cytosolic [Ca2+]i homoeostasis.
To investigate this further we next tested whether insulin
treatment was sufficient to preserve glycolytic flux during
pancreatitis. This was assessed in isolated mouse (C57BL/6)
pancreatic acinar cells in response to the pancreatitis-inducing
agent POA (30 μM) with or without insulin (10 nM) treatment
using the pH-Xtra Glycolysis Assay (Agilent; see Supplementary
Information). This measures extracellular acidification rate
(ECAR), due primarily to lactic acid efflux and thus is a
convenient measure of glycolytic flux. The pH-Xtra assay utilises
a dual-read ratiometric time-resolved fluorescence lifetime
measurement (Fig. S7a), which is converted to extracellular pH
(Fig. S7b) and [H+], using the MARS data analysis software
(See Supplementary Methods) from which ECAR can be
determined and normalised to control (Fig. S7c, mean data).
Insulin (10 nM) alone caused a marginal increase in ECAR
(127 ± 14% of untreated control). However, POA (30 μM)
markedly reduced ECAR to 54 ± 6% of untreated control cells
(Fig. S7), which was restored to similar levels of control (96 ± 5%)
by pre-incubation with insulin (10 nM). These data further
support the notion that insulin maintains glycolytic flux and thus
ATP production to fuel the PMCA, even in the face of POA-
induced metabolic crisis.
The insulin-mediated increase in glycolysis is due to Akt-
mediated phosphorylation of phosphofructokinase fructose
bisphosphatase-2 (PFKFB2). We next wanted to determine the
specific molecular mechanism for the protective effects of insulin
on acinar cells during pancreatitis. Since insulin preserved cellular
ATP and switched metabolism from mitochondrial towards gly-
colysis, we reasoned that the regulation of glycolytic enzymes may
be the primary mechanism. Specifically, we focussed on PI3K/Akt
as the major downstream signalling pathway of insulin, primarily
because in our previous study the PI3K inhibitor, LY294002,
abolished most of insulin’s protection of POA-induced [Ca2+]i
overload in pancreatic acinar cells6. Therefore, we next tested
whether insulin treatment led to the Akt-mediated phosphor-
ylation of key glycolytic enzymes that may be responsible for the
upregulation of glycolysis. This was initially done using co-
immunoprecipitation of all Akt-phosphorylated proteins using
immobilised phospho-Akt-substrate antibody followed by wes-
tern blotting with antibodies for pAkt substrate antibody (positive
control (Fig. S8a) and the key glycolytic enzymes, including
hexokinase-I (HK-I, Fig. S8b), phosphofructokinase-1 (PFK-1,
Fig. S8c), pyruvate kinase-M (PKM, Fig. S8d), pyruvate kinase-L
(PK-L, Fig. S8e), and lactate dehydrogenase-A (LDHA, Fig. S8f).
However, none of these glycolytic enzymes tested were found to
be phosphorylated by Akt following treatment with insulin
(Fig. S8). Although this is not an exhaustive list of Akt substrates,
or even glycolytic enzymes and indeed there may be other
enzymes responsible for the shift towards glycolysis, we decided
to focus on the key glycolytic enzyme reported to be activated by
insulin via Akt-mediated phosphorylation, which is 6-phospho-
fructo-2-kinase/fructose-2,6-biphosphatase 2 (PFKFB2)24. Using
antibodies that specifically detect phospho-Akt (p-Akt(ser473)
and the Akt-mediated phospho-PFKFB2 (p-PFKFB2(ser483))
western blotting showed that treatment of acinar cells from IRlox/
lox mice with insulin (10 nM) for 10 min induced phosphoryla-
tion of Akt and PFKFB2, which was completely abolished by the
PI3K inhibitor LY294002 (10 μM) (Fig. 8). There was a surpris-
ingly high basal Akt and PFKFB2 phosphorylation in untreated
acinar cells from PACIRKO mice compared to acinar cells from
IRlox/lox mice. Importantly, however, there was no further
increase in Akt or PFKFB2 phosphorylation following insulin
treatment of acinar cells from PACIRKO mice, suggesting that
the loss of insulin receptors was responsible for this insulin
insensitivity. In acinar cells from Ela-CreER/+ mice, that express
Cre (similar to PACIRKO) but also express IRs (similar to IRlox/lox),
there was a lower basal Akt and PFKFB2 phosphorylation and
insulin-induced an increase in Akt and PFKFB2 phosphorylation
similar to that observed in IRlox/lox mouse acinar cells (Fig. 8). This
suggests the high basal Akt and PFKFB2 phosphorylation in
PACIRKO mice is due to loss of IRs rather than non-specific effects
of Cre expression.
The high basal Akt and PFKFB2 phosphorylation in PACIRKO
mice was highly consistent and appeared specific for acinar cells
from PACIRKO mice. We, therefore, investigated this further and
reasoned that the upstream insulin receptor substrates (IRS-1 and
IRS-2) may be responsible. Indeed western blotting revealed that
both IRS-1 and IRS-2 expression was upregulated in PACIRKO
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Fig. 5 Insulin-mediated protection against palmitoleic-induced Ca2+
overload is abolished in pancreatic acinar cells from PACIRKO mice.
Representative traces showing POA-induced [Ca2+]i responses (a–d) in
untreated fura-2-loaded pancreatic acinar cells (a, c) and following pre-
treatment with 10 nM insulin for 15min (b, d) from IRlox/lox (a, b) and
PACIRKO (c, d). Cells were also subsequently treated with 30 pM CCK to
test for recoverability and thus cell viability post-POA treatment. Mean
(±SEM) maximum increase in resting [Ca2+]i above baseline (e) and mean
(±SEM) area under the curve (AUC; f) over the treatment and recovery
period in the absence (dark grey bars) or following treatment with 10 nM
insulin (light grey bars). Significance (specific p values as indicated) was
determined by one-way ANOVA with Sidak’s multiple comparisons. Data
were derived from individual values from multiple cells (6-36 cells per
experiment) in the field of view for each experiment. These values were
averaged giving the experimental mean, that were in turn averaged across
multiple experiments (four separate experiments for each experimental
condition, except PACIRKO with POA, n= 5) giving the true mean ± SEM as
indicated in (e, f).
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mice (Fig. S9a, b). In addition, immunoprecipitation of IRS-1 or
IRS-2 followed by subsequent western blotting with the pan-
phosphotyrosine antibody, revealed that IRS1 (Fig. S9c), and to a
lesser extent IRS-2 (Fig. S9d), were hyperphosphorylated.
Furthermore, treatment of acinar cells isolated from IRlox/lox
mice with insulin (10 nM for as little as 1 min), induced
phosphorylation of IRS-1 (Fig. S9c), but not IRS-2 (Fig. S9d),
whereas acinar cells isolated from PACIRKO mice were
insensitive to insulin (Fig. S9b). These data suggest that the high
basal Akt and PFKFB2 were likely due to an upregulation of IRS-
1 and IRS-2 expression and IRS-1 hyperphosphorylation
upstream of Akt and PI3K. The mechanism for this upregulation
of IRS-1/IRS-2 expression and IRS-1 hyperphosphorylation
remains unclear but may reflect some kind of compensatory
mechanism in response to deletion of the insulin receptor (IR).
However, it is important to re-emphasise that insulin treatment of
PACIRKO mouse acinar cells failed to increase phosphorylation
of IRS-1 (Fig. S9c), Akt (Fig. 8a) or PFKFB2 (Fig. 8c), further
supporting the notion that IR deletion prevents insulin-mediated
downstream signalling and thus protection against cellular injury.
On the other hand, insulin treatment of IRlox/lox mouse acinar
cells caused phosphorylation of IRS-1 (Fig. S9c), Akt (Fig. 8a) and
PFKFB2 (Fig. 8c), as one would expect with normal IR
expression.
The expression of Cre has been reported to cause non-specific
toxicity regardless of deletion of specific floxed genes25. However,
there were no signs of pancreatic injury in Ela-CreER/+ mice
(Fig. S3) and CCK-evoked Ca2+ signalling (Fig. S4), POA-
induced Ca2+ overload (Fig. S5) and insulin-mediated Akt
phosphorylation (Fig. 8) were identical in isolated pancreatic
acinar cells from Ela-CreER/+ mice vs IRlox/lox mice. Therefore,
the more severe pancreatitis observed in PACIRKO mice was
most likely due to deletion of IRs and the loss of endogenous
insulin protection of acinar cells, rather than the non-specifc
potentiation of acinar cell injury induced by Cre expression.
Therefore, to reduce the number of mice required for in vivo
studies, experimental pancreatitis was only induced in PACIRKO
and corresponding littermate control IRlox/lox mice.
It is also interesting to note that the pancreatitis-induced
increase in plasma amylase, a classical early diagnostic indicator
of pancreatitis, was blunted in PACIRKO mice compared to
corresponding IRlox/lox mice (Fig. S2d, e). However, this was most
likely due to the reduced pancreatic acinar cell amylase expression
(Fig. S2a–c) and secretion, which is well known to be regulated by
insulin and is reduced in diabetic animals26,27.
Caerulein infusion-induced increase in plasma amylase is
reduced by insulin administration using the hyperinsulinaemic
euglycaemic clamp. Given the protective effect of endogenous
insulin during acute pancreatitis—which was abolished in dia-
betic Ins2Akita mice that lack insulin secretion and PACIRKO
mice that lack acinar insulin receptors—we next wanted to assess
the potential protective effects of exogenously administered
insulin. This was achieved by combining caerulein infusion-induced
acute pancreatitis with continuous insulin infusion with tight































































































































































Fig. 6 Insulin-mediated protection against palmitoleic acid-induced inhibition of the PMCA is abolished in pancreatic acinar cells from PACIRKO mice.
Representative traces showing time-matched control in situ [Ca2+]i clearance experiments (a, d) and the effect of POA (b, e) on [Ca2+]i clearance in
untreated cells (b, e) and cells pre-treated with 10 nM insulin (c, f) in pancreatic acinar cells from IRlox/lox (a–c) and PACIRKO mice (d–f). Cells were
treated with 30 μM CPA (arrow) in the absence of external Ca2+ (1 mM EGTA; white bar) or 20mM Ca2+ (grey bar) to induce store-operated Ca2+ influx
phases. POA was added prior to the re-addition of 20mM external Ca2+.during the second influx-clearance phase (black bar). Inset dashed box (a–f)
shows superimposed expanded time-courses of first (black trace) and second clearance phase (grey trace). Traces are representative of 5 (IRlox/lox time-
matched control, a), 4 (IRlox/lox POA, b), 3 (IRlox/lox POA with insulin, c), 5 (PACIRKO time-matched control, d). 4 (PACIRKO POA, e) and 5 (PACIRKO
POA with insulin, f) separate experiments. Linear clearance rate (in the presence of POA) was normalized to the initial clearance rate in each cell (%
relative clearance rate). g Mean % relative clearance (±SEM) of corresponding time-matched control (white bar), POA treatment (30 μM; dark grey bar),
and POA with insulin (light grey bar). Significance (specifc p values as indicated) was determined by one-way ANOVA with Sidak’s multiple comparisons.
Data were derived from individual values from multiple cells (3-19 cells per experiment) in the field of view for each experiment. These values were
averaged giving the experimental mean, that were in turn averaged across multiple experiments giving the true mean ± SEM as indicated in (g).
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euglycaemic clamp. This allowed continuous high dose exogen-
ous insulin infusion (12 mU/kg/min) and glucose infusion rate
was adjusted according to blood glucose which was monitored
every 10 min (via the arterial line) with a target euglycaemia of
120–130 mg/dl. This high dose insulin (12 mU/Kg/min) infusion
is ~3 times higher than that normally used for insulin clamp
experiments used to determine insulin resistance, and much
higher than the systemic endogenous insulin concentration.
However, we reasoned that this would be necessary because
acinar cells in vivo are reported to be bathed in approximately
10 times higher insulin28,29 compared to the systemic circula-
tion, due to the islet-acinar portal circulation30 (see ref. 31 for a
general description) Initial experiments sought to determine the
optimum caerulein administration by comparing continuous
low dose infusion (10 µg/kg/h), high dose infusion (50 µg/kg/h)
and hourly bolus caerulein (50 µg/kg) injection via the venous
line (to mimic the conventional IP injections used in previous
well-established models, Figs. 1 and 3). Blood samples were
collected (via sampling of the IV line) at time 0, 1 h, 3 h and 5 h
of the experiment for assessment of plasma amylase as an early
readout of pancreatic injury. This revealed that continuous high
dose caerulein infusion (50 µg/kg/h) induced the greatest
increase in plasma amylase at 5 h (23 ± 1.4 Uml−1, n= 4,
Fig. 9e) compared to low dose (10 µg/kg) caerulein infusion (10
± 0.6 Uml−1, n= 4, Fig. 9e) or hourly bolus injections (15 ± 1.7
Uml−1, n= 4, Fig. 9e). Moreover, this high dose caerulein
infusion (50 µg/kg/h) induced a similar increase in plasma
amylase to that induced by 8 hourly IP injections of caerulein
over 2 days (23 ± 2.0, n= 7, Fig. S1f). This suggests that this high
dose caerulein infusion (50 µg/kg/h) was sufficient to induce
pancreatic injury at 5 h and was therefore taken forward for the
combined caerulein infusion and hyperinsulinaemic eugly-
caemic clamp experiments.
Blood glucose was reasonably well maintained during each
experiment (insulin alone, Fig. 9a; combined caerulein/insulin,
Fig. 9b; caerulein alone, Fig. 9c and saline control, Fig. 9d), with
the exception of the spike in blood glucose when glucose infusion
rate was increased to accommodate the onset of insulin infusion
(Fig. 9a, b). This suggests that during high dose insulin infusion,
tight glycaemic control can be maintained by close glucose
monitoring and adjusting glucose infusion rate accordingly.
Measurement of plasma amylase at 5 h revealed that the
caerulein infusion-induced an increase in plasma amylase (14 ±
1.3 Uml−1, n= 6, Fig. 9f) that was significantly reduced by high
dose insulin infusion initiated 2 h after the onset of caerulein
infusion (9 ± 0.6 Uml−1, n= 6, Fig. 9f, p < 0.05). However, insulin
infusion alone had no effect (5 ± 0.5 Uml−1, n= 6, Fig. 9f)
compared to saline control (5.6 ± 0.3 Uml−1, n= 7, Fig. 9f). These
data suggest that exogenous insulin infusion with tight glycaemic
control may reduce early pancreatic injury associated with acute
pancreatitis.
Collectively, these data suggest that endogenous insulin directly
protects pancreatic acinar cells during experimental models of
acute pancreatitis. Loss of insulin secretion (Ins2Akita mice) or
loss of acinar IRs (PACIRKO mice) makes pancreatitis worse.
This increase in severity of pancreatitis in Ins2Akita and
PACIRKO mice was due to a loss of insulin-induced Akt-
mediated phosphorylation of PFKFB2, which normally preserves
glycolytic ATP supply to PMCA and prevents cytotoxic Ca2+


















































































































































Fig. 7 Insulin-mediated protection of POA-induced ATP depletion and switch from mitochondrial metabolism to glycolysis was abolished in PACIRKO
mice. POA concentration-response curves for ATP depletion in the absence and presence of insulin (10 nM) in pancreatic acinar cells isolated from IRlox/lox
(a) and PACIRKO mice (b) and corresponding mean IC50 values (±SEM) (c). Mean data are from eight separate experiments. Significance (exact p values
as indictated) was determined by repeated measures one-way ANOVA with Sidak’s multiple comparisons. NADH autofluorescence was used to assess the
relative mitochondrial vs glycolytic metabolism in pancreatic acinar cells isolated from IRlox/lox (d, e) and PACRIKO mice (g, h). Sequential background-
subtracted images were acquired every 5 s (500ms exposure), and changes in NADH autofluorescence were quantified as raw fluorescence grey levels.
To determine the relative mitochondrial and glycolytic contributions to NADH autofluorescence, the cells were treated with 4 μM CCCP and then 2mM
iodoacetate (IAA), respectively, and responses were normalised to the total (f, IRlox/lox; i, PACIRKO). Mean data (±SEM) from four separate experiments
for each experimental condition, except IRlox/lox with insulin (n= 7). Significance (specifc p values as indicated) was determined by either repeated
measures (c) or ordinary one-way ANOVA (f, i) with Sidak’s multiple comparisons.
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hyperinsulinaemic euglycaemic clamp significantly attenuated
caerulein infusion induced pancreatic injury associated with the
early phase of pancreatitis.
Discussion
The current study provides the first direct evidence that endo-
genously released insulin directly protects pancreatic acinar cell
injury during two mechanistically distinct experimental models of
acute pancreatitis (caerulein and POA/ethanol-induced).
Impaired insulin secretion (which occurs in type-1 diabetic
Ins2Akita mice) and deletion of IRs in pancreatic acinar cells
(which occurs in PACIRKO mice) both led to worse pancreatitis.
Moreover, this study also provides the first evidence that exo-
genous administration of insulin, using the hyperinsulinaemic
euglycaemic clamp, reduces caerulein-induced increase in plasma
amylase and thus acute pancreatic injury.
Heterozygous Ins2Akita male mice exhibit a single point
mutation in the Ins2 gene which gives rise to inappropriate
folding of pro-insulin during its synthesis, leading to ER stress
and the consequent pancreatic β-cell apoptosis32–34. This leads to
the loss of endogenous insulin secretion and the mice sponta-
neously develop early age onset non-obese type-1, insulin-
dependent diabetes33. Ins2Akita mice exhibit no signs of col-
lateral injury or inflammation of neighbouring cells of the islets
(insulitis) or adjacent acinar cells making this strain a good model
for studying the effects of impaired insulin secretion on pan-
creatitis. Indeed, in the current study caerulein-induced pan-
creatitis was more severe in type-1 diabetic Ins2Akita mice;
characterised by pancreatic oedema, tissue injury (vacuoles),
cytokine expression and inflammation19. This is consistent with
clinical evidence that pre-existing diabetes increases the severity
of acute pancreatitis12, diabetes is linked to mortality in patients
with chronic pancreatitis (CP)35,36 and ~50% of type-1 diabetic
patients exhibit pancreatic exocrine lesions characteristic of CP11.
Moreover, the incidence of AP is higher among type-2 diabetics
compared to the normal population and the risk of AP is reduced
among insulin-treated diabetic patients10.
The current data are also consistent with a previous study in
which caerulein-induced pancreatitis was aggravated in strepto-
zotocin (STZ)-induced diabetic mice; both the acute phase of
injury and regeneration of the pancreas (7 days later) was
delayed17. Moreover, this diabetic-induced severe pancreatitis
phenotype was partially corrected by exogenous administration of
insulin. Although generally specific for pancreatic β cells, STZ
may induce collateral exocrine injury37 which may further
aggravate caerulein-induced pancreatitis independent of reduced
insulin secretion. However, the mutation in Ins2Akita mice leads
to a more specific pancreatic β cell death and is more relevant to
the clinical situation making this important when studying the
diabetes-pancreatitis link.
Nevertheless, regardless of the specific diabetes model, it is very
difficult to separate the confounding effects of hyperglycaemia
[which facilitates more severe pancreatitis and sepsis38] or
reduced systemic effects of insulin [which exhibits anti-
inflammatory properties39] from a loss of direct insulin protec-
tion of acinar cells5,6. This can only be achieved using PACIRKO
mice. IR expression is greatly reduced specifically in the pancreas
and PACIRKO mice are normoglycaemic and insulin levels are
normal18, thereby removing the confounding systemic effects of
hyperglycaemia and loss of insulin secretion that occurs in
Ins2Akita mice. The PACIRKO mouse model is essential because
global IR knockout mice develop early postnatal diabetes, die










































































































Fig. 8 Insulin increases Akt phosphorylation and the downstream Akt-mediated phosphorylation of the key glycolytic enzyme, PFKFB2, which is
abolished in acinar cells from PACIRKO mice. Pancreatic acinar cells from IRlox/lox (a–c), PACIRKO (a–c) or Elast-Cre (d–f) were treated with or without
10 nM insulin and/or the PI3K inhibitor, LY294002 (10 μM) for 10min followed by cell lysis. Proteins were separated by SDS-PAGE and western blotted
using antibodies for the insulin receptor (IR, a, c and e), phospho-Akt (Ser473) (a, d), total Akt (b, e) and phospho-PFKFB2 (Ser483) (c and f), which
recognizes the specific Akt consensus phosphorylation site. For each representative experiment shown (a–f) separate gels were run and each membrane
cut and incubated with each corresponding antibody either in parallel or in series, including IR, Akt, pAkt(S473), pFKFB2 and the loading control actin.
These were all sufficiently separated so that they could be resolved on the same gel. Each experiment shown (a–f) is representative of at least three
independent experiments.
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deletion will likely affect embryonic pancreatic development41,42.
Therefore, tamoxifen-induced deletion of IRs in adult PACIRKO
mice circumvents these problems.
Results show that caerulein-induced pancreatitis is also exa-
cerbated in PACIRKO mice, similar to Ins2Akita mice. Specifi-
cally, pancreatic oedema, pancreatic injury/inflammation and
pancreatic cytokine expression were all potentiated in
PACIRKO mice. Caerulein is an analogue of cholecystokinin
(CCK), which at high doses hyperstimulates acinar cells and
induces cytotoxic Ca2+ overload. This mimics the downstream
pathology and is a well-validated model of both acute and
chronic pancreatitis43. However, in most cases of the human
disease, caerulein does not mimic the natural aetiology. There-
fore, it was necessary to compare pancreatitis in PACIRKO vs
IRlox/lox mice using the mechanistically distinct POA/ethanol
(ETOH)-induced experimental model of pancreatitis20. This
model was first established by Huang et al.20, and is more
relevant than other models because not only does it mimic the
downstream pathology of the disease, but also mimics the nat-
ural aetiology of alcohol-induced pancreatitis. In the present
study, we used a slightly lower dose of POA (100 mg/Kg) and
ethanol (0.8 g/Kg), which reduced the collateral intraperitoneal
tissue injury and induced a more specific pancreatitis compared
to ethanol alone (Fig. S1).
Similar to caerulein-induced pancreatitis, we also observed
qualitatively identical potentiation of pancreatitis induced by
POA/ETOH in PACIRKO mice. Collectively, these data suggest
that endogenous insulin directly protects pancreatic acinar cells
during pancreatitis and deletion of acinar IRs, as is the case with
PACIRKO mice, makes pancreatitis worse. The advantage of
using PACIRKO mice is that it removes the confounding effects
of hyperglycaemia or loss of systemic insulin secretion which
occurs in Ins2Akita mice. A similar loss of direct protection of
insulin on pancreatic acinar cells, due to insulin resistance, might
also explain why type-2 diabetics have an ~3 fold increased risk of
developing acute pancreatitis9,13,14,44.
This study also provides the first evidence that exogenous
therapeutic administration of insulin with tight moment-to-
moment glucose control, using the hyperinsulinaemic eugly-
caemic clamp reduces early pancreatic injury (plasma amylase)
associated with acute pancreatitis (AP). Although further pre-
clinical animal studies are required to fully characterise these
responses and optimise the insulin dose regimen, these data
suggest that insulin has bona fide therapeutic potential that could
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Fig. 9 Caerulein infusion-induced increase in plasma amylase is reduced by insulin infusion with tight glycaemic control using the hyperinsulinaemic
euglycaemic clamp. C57BL/6 mice were catheterized via the carotid artery and jugular vein under recover anaesthesia to allow the continuous infusion of
caerulein (to induce acute pancreatic injury), insulin (12 mU/kg/min) and glucose (variable rate) to maintain euglycaemia. Caerulein-induced acute
pancreatic injury was experimentally induced by continuous infusion of caerulein (50 μg/kg/h) over 5 h and plasma amylase was assessed as an early and
immediate readout of pancreatic injury during the course of the experiment (e) and at the end (f). Mice were separated into 4 groups of 6 mice receiving
insulin alone (a), caerulein and insulin (b, insulin added 2 h into the caerulein infusion), caerulein alone (c) or saline control (d). For clarity, data are
presented as mean ± SEM assessed every 10 min during the entire 5 h. The same data are presented as dot plots showing the full data distribution with
lines connecting the mean in Fig. S10. The effect of different caerulein administration regimes were compared on plasma amylase at 0, 1 h, 3 h and 5 h
(mean plasma amylase ± SEM from groups of 4 mice, e) including; bolus caerulein injection (via IV line) every hour (open square), low dose continuous
caerulein infusion (10 μg/kg/h) and high dose continuous caerulein infusion (50 μg/kg/h). This higher dose continuous caerulein infusion (50 μg/kg/h)
induced the maximum increase in plasma amylase at 5 h and was therefore used in combination with the hyperinsulinaemic euglycaemic clamp (b). Mean
plasma amylase (±SEM) from 4 groups of 6 mice measured at 0 and 5 h in saline control, caerulein alone, caerulein with insulin infusion and insulin
infusion alone (f). Significance (exact p values as indicated) was determined by one-way ANOVA with Sidak’s multiple comparisons.
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be translated to patients with severe AP (SAP). This is because the
standard of care for SAP patients on critical care is fluid resus-
citation and supportive nutritional support frequently adminis-
tered via a parenteral IV line. This makes SAP patients on critical
care highly amenable to the hyperinsulinaemic euglycaemic
clamp as a therapeutic strategy.
Insulin therapy is routinely used to specifically treat hyper-
triglyceridaemia (HTG)-induced pancreatitis45,46, characterised
by plasma lipids exceeding 1,000 mg/dL (normal range, 101–150
mg/dL). Although HTG-induced pancreatitis is relatively rare
(~2–10% of all AP cases), HGT is a well-documented aetiological
risk factor for severe disease47. The rationale for insulin treatment
for HTG-induced SAP is to lower plasma triglycerides, thereby
limiting inflammation48. This is because insulin activates lipo-
protein lipase (converts triglycerides into free fatty acids) and
inhibits hormone-sensitive lipase (liberates triglyceride from
adipocyte). However, given the evidence presented in the present
study, it’s entirely possible that the beneficial effects of insulin
therapy in HTG-induced pancreatitis patients may also be due to
a direct protection of acinar cell injury.
Its also worth noting that intensive insulin therapy is the
standard of care for all critically ill patients, regardless of
underlying disease, with the aim of reducing hyperglycaemia
associated with the acute phase of injury which facilitates
inflammation and sepsis49. Although several clinical studies and
meta-analyses question the overall patient benefit50–54, careful
scrutinization of these studies reveal that fewer patients receiving
insulin die from sepsis, but rather die from the complications of
inadvertent hypoglycaemia as a result of inadequate glucose
control. Moreover, it is unclear from any of these studies whether
any SAP patients specifically benefited from intensive insulin
therapy as patients were only identified within broad disease
categories (e.g. GI diseases). Furthermore, the present study used
a relatively high dose insulin infusion (12 mU/kg/min—approx
three times higher than the normal systemic concentration) with
close glucose monitoring (every 10 min) to maintain tight blood
glucose. The rationale for such high dose insulin is because
in vivo pancreatic acinar cells receive a portal blood flow direct
from the islets30 containing approximately ten times higher
insulin concentration than the systemic circulation28,29. Fur-
thermore, stress hormones, such as adrenaline, cortisol and glu-
cagon, and inflammatory cytokines (TNFα and IL-1β) reduce the
tissue sensitivity of insulin, so a higher dose of insulin may be
necessary to overcome this during the acute phase of injury.
The safety record of the hyperinsulinaemic euglycaemic clamp
is well recognised as it is used routinely to test for insulin resis-
tance. Moreover, high dose insulin infusion (8 mU/kg/min;
adjusted for surface area to weight ratio) with tight physiological
glucose control has been tested in healthy human volunteers
during endurance exercise studies with no reported adverse
effects55. Nevertheless, the use of high dose insulin, even with
tight glycaemic control, would have to be approached with cau-
tion in SAP patients in critical care, given the potential problems
of ketoacidosis, hypokalemia or other metabolic disturbances.
The present study also showed, using cellular models of pan-
creatitis, that insulin signalling protects against POA-induced
ATP depletion, inhibition of the PMCA and the consequent
cytotoxic Ca2+ overload. This was due to an insulin-mediated
metabolic shift towards glycolysis, most likely due to Akt-
mediated phosphorylation of the rate-limiting glycolytic enzyme
PFKFB2. This preserves cellular ATP and fuels the PMCA,
thereby maintaining low resting [Ca2+]i, even in the face of
impaired mitochondria by pancreatitis-inducing agents (see
Fig. 10). A conceptually similar ‘boost’ in metabolism and pre-
servation of ATP has been recently suggested to be responsible for
the protective effect of galactose supplementation during
pancreatitis56. Glycolytic enzymes are also reported to be asso-
ciated with the plasma membrane of erythrocytes, smooth muscle
cells and pancreatic cancer cells where they provide a privileged
ATP supply to the PMCA57–64. Cutting off this ATP supply in
pancreatic cancer cells reduced numerous hallmarks of cancer
and induced cytotoxic Ca2+ overload and cell death63,64. If
extrapolated to acinar cells, such insulin-mediated upregulation
of this localized glycolytic ATP supply to the PMCA may be all
the more critical when mitochondria, the major source of ATP,
are impaired and global ATP is severely depleted.
PFKFB2 is a member of the PFKFB family of bi-functional
glycolytic enzymes that convert F6P to F2,6BP, via their kinase
activity, and also catalyzes the reverse reaction by converting
F2,6BP back to F6P, via their bisphosphatase activity24. F2,6BP is a
potent positive allosteric activator of the rate-limiting irreversible
glycolytic enzyme, PFK-1, which converts F6P to F1,6BP, thereby
maintaining glycolytic flux65. The relative kinase to bisphosphatase
activity, and thus the production of F2,6BP, varies between the
different PFKFB isoforms; with PFKFB1/4 expressed in the liver
exhibiting almost no kinase activity, which therefore acts as a break
in glycolysis, promoting glycogen synthesis and flux through the
pentose phosphate pathway important for nucleotide and amino
acid biosynthesis65. On the other hand, PFKFB3 (which is
expressed in cancer cells) has a 700 fold higher kinase activity,
which means that glycolytic flux is essentially maximally activated
and thus contributes to the Warburg effect in cancer cells66.
PFKFB2 is a tunable glycolytic enzyme with approximately equal
kinase vs bisphosphatase activities, but its kinase activity is dra-












Fig. 10 Cartoon depicting the putative molecular mechanism for insulin
protection of pancreatic acinar cells during acute pancreatitis.
Pancreatitis inducing agents, such as fatty acid/ethanol metabolite
palmitoleic acid (POA) impair metabolism, most notably mitochondrial
function, leading to ATP depletion and inhibition of Ca2+ clearance
pathways, such as the plasma membrane Ca2+ ATPase (PMCA), leading to
cytotoxic Ca2+ overload. The net effect of ATP depletion and cytotoxic Ca2+
overload is rapid necrotic cell death, a major hallmark of acute pancreatitis.
Insulin binding to the insulin receptor leads to the downstream activation of
the PI3K/Akt signalling pathway and the direct Akt-mediated
phosphorylation and activation of the key glycolytic enzyme,
phosphofructokinase fructose bisphosphatase-2 (PFKFB2). This leads to the
production of the key glycolytic metabolite fructose 2,6-bisphosphate, which
is an allosteric activator of the rate limiting phosphofructokinase-1 (PFK1),
which in turn drives glycolytic flux and thus glycolytic ATP production and
supply to the PMCA. This appears to be sufficient to maintain acinar cell
ATP and prevent inhibition of the PMCA, even in the face of impaired
mitochondrial function, thereby protecting against necrotic cell death and
the self-perpetuating tissue injury and spiralling inflammatory response
characteristic of acute pancreatitis. During diabetes (Ins2Akita mice) and in
PACIRKO mice, this endogenous insulin protection is abolished, leading to
more severe acute pancreatitis. Moreover, exogenous insulin administration,
using the hyperinsulinaemic euglycaemic clamp to infuse high dose insulin
while maintaining close glucose control, ameliorates or protects against
further pancreatic injury suggesting a potential therapy for severe acute
pancreatitis.
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AMPK65. Therefore, phosphorylation of PFKFB2 acts as a ‘volume
control’ for glycolytic flux and thus ATP production and is thus
likely to be the major molecular mechanism for the protective
effects of insulin during pancreatitis (see Fig. 10).
It is also interesting to note that the expression of amylase was
also reduced in pancreatic acinar cells of PACIRKO mice.
Moreover, the pancreatitis-induced increase in plasma amylase, a
classical early clinical biomarker for pancreatitis, was blunted in
PACIRKO mice. This is particularly interesting because there
have been numerous older studies that show that the expression
and synthesis of amylase is matched by the relative carbohydrate
composition in the diet67–69, which in turn is controlled by
insulin (and insulin receptors within acinar cells)26,27,70. Speci-
fically, fasting reduces acinar amylase, which can be restored by
glucose administration, but this is prevented by diazoxide which
inhibits glucose-dependent insulin secretion71–73. Conversely,
and consistent with the present study, acinar amylase content
(expression and synthesis) is severely reduced in type-1 diabetic
rat models (streptozotocin and alloxan), which is restored by
insulin administration26,27,70. Similarly, acinar amylase content is
also reduced in hyperinsulinaemic insulin-resistant diabetes
models (Zucker rat) and restored by ciglitazone (reduces insulin
resistance and normalizes glucose)74. Therefore, during pan-
creatitis when acinar cells undergo necrosis and thus cell lysis
there is potentially less amylase available to be released into the
interstitium and thus plasma, which helps to reconcile these
results.
It was also observed in Ins2Akita and PACIRKO mice that the
wet/dry weight ratio was significantly lower in mice without
pancreatitis compared to the corresponding control mice (WT or
IRlox/lox, respectively). This suggests that the pancreas tissue is
more dehydrated in Ins2Akita and PACIRKO mice than control
mice, suggesting that endogenous insulin might regulate tissue
water content. However, this is independent of systemic hyper-
glycaemia, and thus osmotic diuresis, as this occurs in PACIRKO
mice that are normoglycaemic. Therefore, this suggests that
insulin regulates acinar cell ion/volume regulation and thus tissue
fluid homoeostasis specifically mediated through activation of
acinar cell IRs. It is interesting to note that insulin, and its
downstream signalling pathways, have been shown to regulate
numerous ion transport pathways, such as Na+/K+/2Cl−
cotransporter (NKCC)75–81 and Na+/K+-ATPase77,79,82,83 that
are critical for regulation of cell volume and thus fluid homo-
eostasis. It is also worth mentioning that the loss of NKCC
activity, for example during inhibition with the loop diuretic
bumetanide, reduces insulin sensitivity in hepatocytes84, sug-
gesting that cell volume regulation is important for maintaining
insulin effectiveness. Therefore, if extrapolated to pancreatic
acinar cells, this suggests that the loss of NKCC activity and cell
volume regulation during diabetes may further exacerbate acinar
cell injury and thus contribute to the severity of pancreatitis.
In summary, the current study provides a mechanistic link
between diabetes and the severity of acute pancreatitis (AP).
Moreover, this study provides evidence that exogenous ther-
apeutic administration of insulin with tight moment-to-moment
glucose control, using the hyperinsulinaemic euglycaemic clamp
reduces early pancreatic injury associated with AP. Therefore,
insulin infusion with the aim of reducing pancreatic injury may
prove effective for the treatment of SAP, as long as there is tight
moment-to-moment glycaemic control (hyperinsulinaemic
euglycaemic clamp). Finally, the present study has identified
phosphorylation of PFKFB2 as a potential therapeutic strategy for
the design of new drugs, or the repurposing of existing drugs, for
the treatment of AP. In addition to Akt-mediated phosphoryla-
tion, PFKFB2 can be phosphorylated at the exact same serine
residue (S483) by AMP-dependent kinase (AMPK) and/or
protein kinase-A, suggesting that AMPK activators or drugs that
elevate cAMP might mimic the protective effects of insulin.
Interestingly, the anti-diabetic drug metformin is also an AMPK
activator, suggesting that this could be repurposed to treat acute
pancreatitis. Such drugs might have a more specific protective
effects without some of the more adverse systemic effects, tech-
nical difficulties or safety issues of insulin administration that
could be used to treat all forms of acute pancreatitis from mild to
severe disease.
Methods
Further information and requests for resources, reagents and access to data should
be directed to Jason Bruce (jason.bruce@manchester.ac.uk). A more comprehen-
sive description of the methods and list of reagents can be found in Supplementary
Information. All studies with research animals, including in vivo experiments and
experiments using cells/tissues derived from research animals complied with all
relevant ethical regulations regarding the use of research animals (see below).
Animal study approval. All animal procedures and in vivo experiments were
approved by the University of Michigan Institutional Animal Care and Use
Committee (IACUC). The breeding of PACIRKO mice and feeder strains (Ela-
CreER/+ and IRlox/lox) at the University of Manchester, which includes the
administration of tamoxifen to induce insulin receptor deletion was approved by
the Home Office Project licence (PPL number, P08B76E2B; PPL holder, Michael
Simonson-Jackson).
Ins2Akita and PACIRKO mice. All experiments using Ins2Akita mice were per-
formed on male heterozygous mice at 6–9 weeks, as this was empirically deter-
mined to be the time of onset of consistent hyperglycaemia. Ins2Akita mice were a
kind gift from Peter Arvan (Department of Internal Medicine, Unversity of
Michigan). PACIRKO mice were originally generated from the feeder strains
Elastase-Cre-ER mice (Elast-CreER/−) double floxed insulin receptor mice (IRlox/
lox) as previously described18. Both the experimental mice (PACIRKO) and age-
matched littermate control mice (IRlox/lox) were administered tamoxifen (75 mg/
kg) by oral gavage daily for 4 days at 5–6 weeks and on day 7 pancreatitis was
induced using either caerulein or POA/ETOH. IR expression was confirmed and
western blotting with an anti-IRβ antibody (Cell Signaling). For additional details
about breeding and genotyping of Ins2Akita and PACIRKO mice see Supplemen-
tary Information. All mice are kept in individually ventilated cages with 12 h light:
12 h dark cycles maintained at 22 °C ± 2 °C and between 45 and 65 relative
humidity with free access to food and water. These conditions are in accordance
with the Codes of Practice for the care and accommodation of animals under
section 21 of the Animals (Scientific Procedures) Act 1986 as amended in 2012
(‘ASPA’).
Caerulein-induced experimental pancreatitis. Mice received eight hourly intra-
peritoneal (IP) injections of 50 μg/Kg caerulein per day over two consecutive days
and were euthanized by CO2 asphyxiation followed by cervical dislocation 2 h or
24 h after the last caerulein injection. Blood was immediately collected for
assessment of blood glucose and plasma amylase (Phadebas amylase test, Magle
Life Sciences). Whole pancreas tissue was rapidly dissected, weighed and cut into
sections for processing for histology (10% formalin), RNA (RNA later, Thermo-
Fisher), protein (snap frozen in liquid nitrogen, prior to homogenisation in lysis
buffer) and wet/dry weight ratio (weighed before and after drying in an oven at 90 °
C for 24 h).
POA/ETOH-induced experimental pancreatitis. Mice received one IP injection
containing PBS followed by two hourly IP injections of 100 µg/Kg POA, 0.8 g/Kg
ethanol (ETOH). This was a slightly lower dose of POA and ETOH used in the
study that originally characterised this model20 and was fully optimized in the
current study to produce the least collateral organ injury and a more specific
pancreatitis (Supplementary Information). Similar to the caerulein model, mice
were euthanized 2 h or 24 h after the last injection and tissue/blood were harvested
and processed in the same way.
RNA extraction and quantitative real time PCR. Pancreatic tissue stored at 4 °C
in RNA later was transferred to TRIzol reagent (Ambion Life Technology) and
homogenised using a polytron for 5–10 s. RNA was isolated using chloroform/
isopropanol extraction and RNeasy spin column kit (Qiagen). Following quanti-
fication and assessment of purity using the Nanodrop 280/260 nm optical density
ratio (OD280/OD260 ratios), isolated (200 ng) was reverse transcribed into cDNA
using TaqMan reverse transcription reagents (Thermofisher) with random hex-
amers as primers. Quantitative PCR reactions were carried out using the Absolute
Blue SYBR Green ROX reagent (Thermo Scientific, Waltham, MA) with specific
primers (listed in Supplementary Table 1 and ref. 85).
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SDS PAGE and western blotting. Frozen tissue that had been snap-frozen in
liquid nitrogen following dissection was homogenized in lysis buffer (in mM: 50,
Tris-HCl; 50, NaCl; 5, EDTA, 0.2% triton X-100; 10 mM NF; 10, Na4P2O7; 25,
glycerophosphate, 1, DTT; 1, PMSF; 0.2, Na3VO4; 10 µg/ml leupeptin; 10 µg/ml
aprotinin). For phosphorylation assays (phospho-Akt and phosphor-PFKFB2),
isolated pancreatic acinar cells were resuspended in a similar lysis buffer containing
protease inhibitor cocktail tablets (Roche) and PhosSTOP (Roche). Lysates were
allowed to solubilize at 4 °C for 30 min followed by sonication and centrifugation at
16,000 × g for 10 min to remove insoluble debris (pellet). Sample protein was
determined (Bradford assay, Bio-Rad Laboratories), denatured by boiling in SDS-
Laemmli buffer for 5 min, separated using sodium dodecyl sulphate
electrophoresis-polyacrylamide gel electrophoresis (SDS-PAGE), transferred to
nitrocellulose and western blotted using specific antibodies at 1:1000 dilution
(unless otherwise stated) to insulin receptor (IRβ mAB), amylase (rabbit anti-α-
amylase, used at 1:15,000 dilution), Akt1 (C73H10) (rabbit mAb used at 1:14,000)
phospho-Akt substrate, phospho-Akt (Ser473) (used at 1:15,000 dilution),
phospho-PFKFB2 (Ser483) (used at 1:5,000 dilution), IRS-1 (rabbit MAb;), IRS-2
(mouse MAb), pan-phosphotyrosine (clone 4G10; used at 1:8,000 dilution), HKI,
PFK-1, PKM, PKL/R, LDH and actin (used at 1:100,000) or cyclophilin-A were
used as a loading control (Supplementary Table 1, Supplementary Information).
For immunoprecipitation, cells were lysed in Radioimmune Precipitation Assay
(RIPA) buffer (containing 50 mM Trizma® base, 1 mM EDTA, 1 mM EGTA, 0.1
mM vanadate, 1 mM NaF, 40 mM Na4P2O7, 1% Triton X-100, 0.1% SDS, and
supplemented with cOmplete EDTAfree protease inhibitors and PhosSTOP
phosphatase inhibitors), sonicated and left to solubilize for 30 min on ice86. Protein
lysates containing around 1mg/ml of protein were incubated with either IRS-1 or
IRS-2 antibody (1 ml lysate; 1:100 dilution) overnight at 4 °C on a rocking plat-
form. Protein lysates were incubated for a further 2 h at 4 °C with magnetic
protein-G Dynabeads. Immunoprecipitates were washed five times with lysis
buffer, denatured in SDS Laemmli sample buffer and boiled for 15 min at 100 °C.
Immunoprecipitated samples were then separated by SDS and western blotted.
Plasma amylase. Frozen plasma harvested from experimental mice was slowly
defrosted and assayed for amylase concentration using Phadebas reagent (Sup-
plementary Information).
Histological assessment of pancreatitis. Pancreatic tissue was formalin-fixed
(10% formalin at 4 °C for 24 h, followed by 70% ethanol) and paraffin-embedded
(FFPE), prior to cutting into 5 μm sections and mounting onto slides (Supple-
mentary Information). Tissue sections were stained with haemotoxylin and eosin
(H&E) using a standard protocol by the University of Michigan Cancer Center
Histology Core Facility. All pancreatic tissue sections were imaged, archived and
analysed using the 3D-Histech Pannoramic-250 microscope slide-scanner (Uni-
versity of Manchester Bioimaging Facility) (Supplementary Information). Slides
from all animal groups were graded by two independent, blinded observers
according to severity and extent of oedema, inflammatory cell infiltration and
acinar necrosis using a well-validated histology injury score on a scale of 0–3
(where 3 was the most severe). The total score was the sum of the oedema,
inflammation and necrosis scores for each slide (maximum score of 9)87. To fur-
ther assess pancreatic tissue inflammation, immunohistochemistry using anti-
CD45 antibody (1:50 dilution) was performed on FFPE pancreatic tissue sections
(Supplementary Information).
Pancreatic acinar cell isolation. Pancreatic acinar cells from IRlox/lox, PACIRKO
and Ela-CreER/+ mice were isolated by collagenase-digestion which was adapted
from previous methods23,88 and described in detail in Supplementary Information.
Mice were humanely killed by an approved method as set out in Schedule 1 of the
UK Animals Scientific Procedures Act 1986 (Certificate of Designation No 50/
2506). Briefly, following rapid dissection the pancreas was chopped and incubated
in HEPES-buffered physiological saline (HEPES-PSS; for composition see Sup-
plementary Information) containing 0.15 mgml collagenase P (~200 U/ml) and
0.15 mg/ml of soybean trypsin inhibitor (Sigma) for 25 min at 37 °C with
mechanical trituration every 5 min to break up the tissue into small cell clusters.
Cell clusters were resuspended in Dulbecco’s Modified Eagle Medium (DMEM)
containing 2.5% FBS, and 0.15 mg/ml of trypsin inhibitor and left to rest for 30 min
at 37 °C prior to any experimentation.
Imaging of fura-2 fluorescence. Pancreatic acinar cells were loaded with 4 μM
fura-2-AM for 30 min at room temperature in HEPES-PSS and imaged using a
Nikon TE2000S microscope with ×40 oil immersion SFluor objective lens, Cool-
SNAP HQ CCD camera (Photometrics, Tucson, AZ), Cairn monochromator
(Cairn Research, Kent, UK) and MetaFluor imaging software (Molecular Devices,
Downington, PA)23. Background-subtracted fluorescence images were captured
with 50 ms exposure and 5 × 5 binning every 5 s. The fura-2 fluorescence was
calibrated into [Ca2+]i using the well-established Grynkiewicz method88. All
imaging experiments were carried out at room temperature (20–22 °C).
In situ Ca2+ clearance assay. Cells were treated with the sarco/endoplasmic
reticulum Ca2+-ATPase (SERCA) inhibitor, cyclopiazonic acid (CPA) in zero
external Ca2+ (0 Ca2+, 1 mM EGTA) to depelete ER Ca2+ and activate store-
operated Ca2+ entry (SOCE). Addition of 20 mM external Ca2+, therefore, results
in a rapid increase in [Ca2+]i which reaches a steady state and the subsequent
removal of external Ca2+ (0 Ca2+, 1 mM EGTA) causes a rapid [Ca2+]i clearance
due predominantly to PMCA activity. Repeated Ca2+ influx-efflux phases allow
POA to be applied during the second phase and compared to the initial clearance
phase. [Ca2+]i clearance rate (and thus PMCA activity) in the presence or absence
(time-matched control) of POA during this second clearance phase is quantified by
measuring the linear rate from a standardised value of [Ca2+]i and normalised to
the corresponding linear rate during the first clearance phase23.
Measurement of cellular ATP. ATP depletion was assessed using fire-fly luci-
ferase (ViaLight® Plus kit; Lonza, Rockland, ME USA) as previously described5.
Cells were treated with or without 10 nM insulin for 20 min, followed by treatment
with or without various concentrations of POA (1–100 µM). In the same 96 well
plate some wells were treated with an ATP depletion cocktail, consiting of 4 μM
CCCP, 500 μM bromopyruvate, 10 μM oligimycin and 2 mM iodoacetate, for a
further 20 min to induce maximum ATP depletion. The total luminescence count
of the ATP-depletion cocktail was subtracted from each corresponding assay
condition prior to normalisation to the corresponding time-matched controls and
expressed as a % and data presented as sigmoidal concentration-response curves.
Imaging of NADH Autofluorescence. Pancreatic acinar cells were excited with
light at 350 nm (500 ms exposure) and NADH autofluorescence collected through a
fura-2 400 nm dichroic filter without a band pass filter. Sequential background-
subtracted images were acquired every 5 sec and changes in NADH auto-
fluorescence quantified as raw fluorescence grey levels. To determine the relative
mitochondrial and glycolytic contributions to NADH autofluorescence, cells were
treated with 4 µM CCCP and then 2 mM iodoacetate (IAA), respectively.
Imaging magnesium green (MgGreen) fluorescence. Pancreatic acinar cells
isolated from IRlox/lox mice were loaded with 4 µM MgGreen acetoxymethyl ester
(AM) for 30 min at room temperature (see Supplementary Information and
refs. 5,6).
Measurement of glycolysis using the pH-Xtra Glycolysis Assay. Acinar cell
glycolysis was assessed by real-time, kinetic analysis of extracellular acidification
rate (ECAR) using a pH-Xtra Glycolysis Assay kit (Agilent) and a plate reader with
time-resolved fluorescence (TRF) capability (CLARIOstar, BMG Labtech). Extra-
cellular acidification is mainly due to lactic acid efflux, which results in a reduction
in assay buffer pH. The pH Xtra probe sensitively detects this reduction in pH as an
increase in sensor signal. Briefly, isolated mouse pancreatic acinar cells were
washed three times with respiration buffer and pre-incubated in the presence or
absence of 10 nM insulin for 30 min followed by the addition of 30 μM POA. After
15 min, 40 μl of cell suspension per condition was transferred to a 96 half area well
plate and 10 μl of pH-Xtra reagent (fluorescent probe) was added to each well.
Blank control wells were included and cell-free negative and positive (glucose
oxidase) wells were used as signal controls. Each condition was carried out in
triplicate. Both the metabolic incubations and the measurements were carried out
at 37 °C.
Dual read TRF lifetime detection mode was performed and the change in
fluorescent lifetime from 100 to 300 µs delay and a 30-µs read window (excitation
340 ± 50 nm, emission 615 ± 18 nm) was monitored over time. The two TRF
intensity readings collected were used to calculate the ratio-metric fluorescence
lifetimes using a data analysis software (MARS, BMG Biotech), which applies the
following formula: Lifetime (μs)[τ]= (D2−D1)/ln(IW1/IW2) where IW1 and IW2
represent the two (dual) measurement windows and D1 and D2 represent the delay
time prior to measurement of W1 and W2, respectively. Lifetime values (μs) were
corrected based on the blank wells and represent the extracellular acidification in
each individual sample, then scaled to [H+] using the same software tool.
Combined caerulein infusion-induced pancreatitis and hyperinsulinaemic
euglycaemic clamp. Mice (C57BL/6) were anesthetized with an intraperitoneal
injection of sodium pentobarbital (50–60 mg/kg). The ventral side of the neck and
back of the head were shaved and the skin repeatedly scrubbed with iodine and
70% ethanol. Under aseptic conditions, a small incision at the right ventral side of
neck was made cephalic to the sternum at 30° to the midline, exposing the right
carotid artery and jugular vein. The right jugular vein was catheterized using silicon
tubing (0.025′′OD). The right carotid artery was catheterized using a two-part
catheter constructed from polyurethane (0.010′′OD, with interior coated with
heparin) and silastic tubing (0.025′′OD). The arterial catheter was inserted reaching
the level of the aortic arch and the venous catheter was extended to the level of the
right atrium. To allow free movement of the animal post-recovery, the free ends of
catheters were tunnelled subcutaneously and exteriorized at the back of the neck
via a stainless steel tubing connector (coated with medical silicon) that were fixed
subcutaneously upon the closure of the incision. The catheters were flushed daily
after surgery with saline and sealed with heparin-saline (200 U/ml). Following
surgery, mice were allowed to recover and acclimatize for 5 days prior to experi-
mentation and were housed individually and their body weight monitored daily.
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Animals that had the healthy appearance, normal activity, and body weight
regained to or above 90% of their pre-surgery level were used for the study.
Mice were fasted for 5–6 h prior to beginning the caerulein infusion/insulin
clamp. The exteriorized catheters were connected to a series of automated syringe
minipumps (Pump 11 Elite, Harvard Apparatus) to allow the separate adjustment
of infusion rate for saline, caerulein, insulin and glucose. A blood sample (~100 µl)
was taken 10 min prior to the start of the caerulein infusion/insulin clamp (t=
−10 min), for assessment of blood glucose (Accu-Chek glucose meter, Roche). The
caerulein infusion (and corresponding saline control) and insulin clamp (insulin
control) were begun at time zero (t= 0). For the combined caerulein infusion/
insulin clamp, the insulin clamp was begun 2 h into the caerulein infusion (t= 2 h).
Initial experiments sought to determine the optimum caerulein administration by
comparing low dose infusion (10 μg/kg/h), high dose infusion (50 μg/kg/h) and
hourly bolus injection (50 μg/kg), via the venous line (to mimic IP injections of
caerulein used in previous well-established models, Figs. 1 and 3). The insulin
clamp was begun with a prime-continuous infusion (16 mU/kg bolus, followed by
12.0 mU/kg/min or 72 pmol/kg/min) of human insulin (Novo Nordisk) and
continued for either 5 h (insulin control) or the remaining 3 h (combined
caerulein/insulin). Tight glycaemic control (target euglycemia of 120–130 mg/dL)
was maintained during the insulin clamp by measuring blood glucose every 10 min
starting at t= 0 and infusing 50% glucose at variable rates accordingly. Blood
samples were collected every 10 min via the arterial line for assessment of plasma
amylase as an early readout of pancreatic injury at the end of the 5 h infusion
experiment. A continuous infusion of erythrocytes obtained from donor mice via
cardiac puncture was given at 4 µl/min throughout the experiment period to
prevent anaemia from the repeated blood sampling.
Quantification and statistical analysis. For all experiments data are presented as
representative trace, gels and histological image of at least 3–8 separate experiments
and average data are presented as a combined scatter plot (to show individual data
points) and bar chart with mean (±SEM). All data were analysed, transformed and
figures generated using Graphpad prizm v7 and Microsoft Excel 2010. Statistical
significance was determined using either a two-way Students T-test, one-way
ANOVA with Sidak’s multiple comparison, repeated measures one-way ANOVA
with Sidak’s multiple comparison or Kruskal–Wallis test with Dunn’s multiple
comparison (if non-parametric) to determine significance. The specific tesdt used
was included in legend text for each figure.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
All data generated or analysed during this study are included in this published article
(and its Supplementary information files). Source data are provided with this paper and
contains uncropped western blot images, original histological images and the raw data
with a transparent audit trail of how these data have been transformed, normalized and
averaged thereby underpinning the final data shown in the final figures of the
manuscript. Source data are provided with this paper.
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